Shahneen Sandhu

A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol.

David Pryor, Mathias Bressel, Nathan Lawrentschuk, Ben Tran, Jennifer Mooi, Jeremy Lewin, Arun Azad, Duncan Colyer, Nitika Neha, Mark Shaw, Sarat Chander, Paul Neeson, Daniel Moon, Katharine Cuff, Simon Wood, Declan G Murphy, Shahneen Sandhu, Sherene Loi, Shankar Siva

Journal article  |  2021  |  Contemporary Clinical Trials Communications

Background: The management of oligometastatic clear cell renal cell carcinoma (ccRCC) varies widely, ranging from observation to r..

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.

Nattakorn Dhiantravan, John Violet, Renu Eapen, Omar Alghazo, Mark Scalzo, Price Jackson, Simon P Keam, Catherine Mitchell, Paul J Neeson, Shahneen Sandhu, Scott G Williams, Daniel Moon, Nathan Lawrentschuk, Arun Azad, Michael S Hofman, Declan G Murphy

Journal article  |  2020  |  European Urology Focus

LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium..

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

Justin Ferdinandus, John Violet, Shahneen Sandhu, Rodney J Hicks, Aravind S Ravi Kumar, Amir Iravani, Grace Kong, Tim Akhurst, Sue Ping Thang, Declan G Murphy, Scott Williams, Michael S Hofman

Journal article  |  2020  |  European Journal of Nuclear Medicine and Molecular Imaging

PURPOSE: We analysed quantitative biomarkers derived from both baseline whole-body imaging and blood serum to identify prognostic ..

The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary

David L Kok, Annie Wang, Wen Xu, Margaret ST Chua, Alexander Guminski, Michael Veness, Julie Howle, Richard Tothill, Ganessan Kichendasse, Michael Poulsen, Shahneen Sandhu, Gerald Fogarty

Journal article  |  2020  |  Asia Pacific Journal of Clinical Oncology

Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.

Jenny H Lee, Alexander M Menzies, Matteo S Carlino, Ashleigh C McEvoy, Shahneen Sandhu, Alison M Weppler, Russell J Diefenbach, Sarah-Jane Dawson, Richard F Kefford, Michael J Millward, Zeyad Al-Ogaili, Thien Tra, Elin S Gray, Stephen Q Wong, Richard A Scolyer, Georgina V Long, Helen Rizos

Journal article  |  2020  |  Clinical Cancer Research

PURPOSE: Brain involvement occurs in the majority of patients with metastatic melanoma. The potential of circulating tumor DNA (ct..

The DNA methylation landscape of advanced prostate cancer

Shuang G Zhao, William S Chen, Haolong Li, Adam Foye, Meng Zhang, Martin Sjostrom, Rahul Aggarwal, Denise Playdle, Arnold Liao, Joshi J Alumkal, Rajdeep Das, Jonathan Chou, Junjie T Hua, Travis J Barnard, Adina M Bailey, Eric D Chow, Marc D Perry, Ha X Dang, Rendong Yang, Ruhollah Moussavi-Baygi, et al.

Journal article  |  2020  |  Nature Genetics

Although DNA methylation is a key regulator of gene expression, the comprehensive methylation landscape of metastatic cancer has n..

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆.

CN Owen, AN Shoushtari, D Chauhan, DJ Palmieri, B Lee, MW Rohaan, J Mangana, V Atkinson, F Zaman, A Young, C Hoeller, P Hersey, R Dummer, MA Khattak, M Millward, SP Patel, A Haydon, DB Johnson, S Lo, CU Blank, et al.

Journal article  |  2020  |  Annals of Oncology

BACKGROUND: Anti-programmed cell death protein 1 (PD-1) antibodies (PD1) prolong recurrence-free survival in high-risk resected me..

Efficacy and Safety of Lu-177-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study

Andrei Gafita, Wolfgang P Fendler, Wang Hui, Shahneen Sandhu, Manuel Weber, Rouzbeh Esfandiari, Jeremie Calais, Isabel Rauscher, Hendrik Rathke, Robert Tauber, Ebrahim S Delpassand, Wolfgang A Weber, Ken Herrmann, Johannes Czernin, Matthias Eiber, Michael S Hofman

Journal article  |  2020  |  European Urology

The 177Lu-labeled prostate-specific membrane antigen (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate ca..

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

Nikhil Khushalani, Adi Diab, Paolo A Ascierto, James Larkin, Shahneen Sandhu, Mario Sznol, Henry B Koon, Anthony Jarkowski, Ming Zhou, Paul Statkevich, William J Geese, Georgina Long

Journal article  |  2020  |  Future Oncology

Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone

Katie L Owen, Linden J Gearing, Damien J Zanker, Natasha K Brockwell, Weng Hua Khoo, Daniel L Roden, Marek Cmero, Stefano Mangiola, Matthew K Hong, Alex J Spurling, Michelle McDonald, Chia-Ling Chan, Anupama Pasam, Ruth J Lyons, Hendrika M Duivenvoorden, Andrew Ryan, Lisa M Butler, John M Mariadason, Tri Giang Phan, Vanessa M Hayes, et al.

Journal article  |  2020  |  EMBO Reports

The latency associated with bone metastasis emergence in castrate-resistant prostate cancer is attributed to dormancy, a state in ..